-transparent.png){kind=logo}
BACKGROUND Continuous intravenous infusion of prostacyclin is an effective treatment for primary pulmonary hypertension. This approach, however, requires the insertion of a permanent central venous catheter with the potential risk of serious complications. Recently, administration of aerosolized iloprost, a stable prostacyclin analogue, has been introduced as an alternative therapy for severe pulmonary hypertension. METHODS We evaluated the effects of treatment with aerosolized iloprost over a one-year period on exercise capacity and hemodynamic variables in patients with primary pulmonary hypertension. RESULTS Twenty-four patients with primary pulmonary hypertension received aerosolized iloprost at a cumulative daily dose of 100 to 150 micrograms for at least one year. The mean (+/- SD) walking distance in the 6-min-walk test increased from 278 +/- 96 meters at base line to 363 +/- 135 meters after 12 months (P < 0.0001). During the same period, the mean pulmonary artery pressure declined from 59 +/- 10 mmHg to 52 +/- 15 mmHg (P = 0.006), the cardiac output increased from 3.8 +/- 1.4 l/min to 4.4 +/- 1.3 l/min (P = 0.02), and the pulmonary vascular resistance declined from 1.205 +/- 467 dynes.s.cm-5 to 925 +/- 469 dynes.s.cm-5 (P = 0.0003). Treatment was generally well tolerated and except for mild coughing, minor headache and jaw pain in some patients, no side effects occurred. CONCLUSIONS Long-term treatment with aerosolized iloprost is safe and has sustained effects on exercise capacity and pulmonary hemodynamics in patients with primary pulmonary hypertension.
M M Hoeper, and
M Schwarze, and
S Ehlerding, and
A Adler-Schuermeyer, and
E Spiekerkoetter, and
J Niedermeyer, and
M Hamm, and
H Fabel
July 2002,
Anales espanoles de pediatria,
M M Hoeper, and
M Schwarze, and
S Ehlerding, and
A Adler-Schuermeyer, and
E Spiekerkoetter, and
J Niedermeyer, and
M Hamm, and
H Fabel
May 2010,
Respiratory medicine,
M M Hoeper, and
M Schwarze, and
S Ehlerding, and
A Adler-Schuermeyer, and
E Spiekerkoetter, and
J Niedermeyer, and
M Hamm, and
H Fabel
January 2004,
Drugs,
M M Hoeper, and
M Schwarze, and
S Ehlerding, and
A Adler-Schuermeyer, and
E Spiekerkoetter, and
J Niedermeyer, and
M Hamm, and
H Fabel
August 2012,
Cardiology in the young,
M M Hoeper, and
M Schwarze, and
S Ehlerding, and
A Adler-Schuermeyer, and
E Spiekerkoetter, and
J Niedermeyer, and
M Hamm, and
H Fabel
June 2001,
The European respiratory journal,
M M Hoeper, and
M Schwarze, and
S Ehlerding, and
A Adler-Schuermeyer, and
E Spiekerkoetter, and
J Niedermeyer, and
M Hamm, and
H Fabel
July 2001,
The European respiratory journal,
M M Hoeper, and
M Schwarze, and
S Ehlerding, and
A Adler-Schuermeyer, and
E Spiekerkoetter, and
J Niedermeyer, and
M Hamm, and
H Fabel
January 2001,
The European respiratory journal,
M M Hoeper, and
M Schwarze, and
S Ehlerding, and
A Adler-Schuermeyer, and
E Spiekerkoetter, and
J Niedermeyer, and
M Hamm, and
H Fabel
August 2003,
Annals of internal medicine,
M M Hoeper, and
M Schwarze, and
S Ehlerding, and
A Adler-Schuermeyer, and
E Spiekerkoetter, and
J Niedermeyer, and
M Hamm, and
H Fabel
February 2011,
Pulmonary pharmacology & therapeutics,
M M Hoeper, and
M Schwarze, and
S Ehlerding, and
A Adler-Schuermeyer, and
E Spiekerkoetter, and
J Niedermeyer, and
M Hamm, and
H Fabel
March 2009,
European respiratory review : an official journal of the European Respiratory Society,
